Looking Ahead, to December 2023
As I’ve stated, my Anavex investment assessment time frame lasts until 2023. I believe it may take until then to determine if my moderate purchase of AVXLs is profitable or a loss.
So, here are statements I’ll be glad to post in the last week of December, 2023.
If AVXL has lost all value; has no prospect of attaining my share buy-in values, I’ll post this statement:
“Well, 2023 is coming to an end. Unfortunately, after holding my AVXL position for over eight years, it has been a total loss. Originally, I purchased a small position, believing from both murine and early human trials data that Anavex Life Sciences Corp had unique sigma-1receptor agonists that would provide useful treatments for various human central nervous system diseases. However, comprehensive human trials failed, the company failed to attain regulatory approvals to sell their drugs anywhere in the world; it is now a bust.
Fortunately, I didn’t bet my ranch on the investment endeavor; used only budgeted discretionary funds. My best hope is that some new chemotherapeutic approach to CNS diseases might eventually appear. The real loss has been for those suffering from Rett syndrome, Parkinson’s dementia, and Alzheimer’s. Here’s hoping for effective, new treatments.”
Or, if Anavex has proven to be a CNS treatment and commercial success, my statement in December 2023 will be something to this effect:
“It’s been now over eight years since I took my small AVXL position. At the start, for over three years, there was minimal human evidence of treatment success. But, then, in 2019, human trials data concerning Anavex 2-73 against Rett syndrome, Parkinson’s dementia, and Alzheimer’s disease began to appear. Today, those three (and other) human CNS diseases are being successfully prevented and treated by Anavex. Neurology is no longer the same.
And neither is my brokerage account. I’ve determined to continue to hold all of my AVXL shares, now approaching $400 each in value. They will go to my children. The dividends are more than adequate for me. And, now, with the impending approval of Anavex 3-71 and the other new sigma-1 receptor agonist drugs in the still-emerging Anavex pipeline, targeting now many diseases and conditions beyond those of the CNS, the Anavex share price on the NYSE continues to ascend.
So glad I didn’t listen to those distant naysayers, who thought efficacy data for the Anavex molecules were invalid and insufficient. For my career, I taught biochemistry, cytology, etc. My knowledge of those cogent topics allowed me to see the potentials of Anavex—now realized. My best to all; especially to those who formerly would have been suffering from the now-conquered CNS diseases. Thank you, Anavex.”
___________
Which of those will it be?
AI
